Human Amniotic Fluid for the Treatment of Hospitalized, Symptomatic, and Laboratory-verified SARS-CoV-2 Patients

M. Barati, F. Rahim
{"title":"Human Amniotic Fluid for the Treatment of Hospitalized, Symptomatic, and Laboratory-verified SARS-CoV-2 Patients","authors":"M. Barati, F. Rahim","doi":"10.2174/1874196702109010036","DOIUrl":null,"url":null,"abstract":"New reports offer evidence that under different circumstances, intrauterine mother-infant transmission of SARS-CoV-2 occurs. In contrast, early observations in the COVID-19 pandemic recommended that vertical transmission from women infected with SARS-CoV-2 can be challenging and no virus is detected in human amniotic fluid (HAF). The present study aimed to propose the idea that HAF can be used as a potential therapy for hospitalized, symptomatic, and laboratory-verified SARS-CoV-2 patients by mitigating COVID-19 related inflammation and decreasing its fibrosis. Considering that COVID-19 can cause a severe pulmonary fibrotic response in some patients, HAF by decreasing fibrosis may be considered as an alternative and novel therapy against COVID-19. Lastly, given the inexpensive, easy to access, and safe nature of HAF, integrating this therapy may decrease the COVID-19 attributed death and burden to the health system, especially in countries with limited access to vaccines where HAF is widely available.","PeriodicalId":22949,"journal":{"name":"The Open Biology Journal","volume":"5 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open Biology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874196702109010036","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

New reports offer evidence that under different circumstances, intrauterine mother-infant transmission of SARS-CoV-2 occurs. In contrast, early observations in the COVID-19 pandemic recommended that vertical transmission from women infected with SARS-CoV-2 can be challenging and no virus is detected in human amniotic fluid (HAF). The present study aimed to propose the idea that HAF can be used as a potential therapy for hospitalized, symptomatic, and laboratory-verified SARS-CoV-2 patients by mitigating COVID-19 related inflammation and decreasing its fibrosis. Considering that COVID-19 can cause a severe pulmonary fibrotic response in some patients, HAF by decreasing fibrosis may be considered as an alternative and novel therapy against COVID-19. Lastly, given the inexpensive, easy to access, and safe nature of HAF, integrating this therapy may decrease the COVID-19 attributed death and burden to the health system, especially in countries with limited access to vaccines where HAF is widely available.
人羊水用于治疗住院、有症状和实验室证实的SARS-CoV-2患者
新报告提供的证据表明,在不同情况下,会发生SARS-CoV-2的母婴宫内传播。相比之下,COVID-19大流行的早期观察结果表明,感染SARS-CoV-2的女性的垂直传播可能具有挑战性,并且在人羊水(HAF)中未检测到病毒。本研究旨在提出这样一种观点,即HAF可以通过减轻COVID-19相关炎症和减少其纤维化,作为住院、有症状和实验室验证的SARS-CoV-2患者的潜在治疗方法。考虑到COVID-19可在部分患者中引起严重的肺纤维化反应,通过减少纤维化的HAF可被视为对抗COVID-19的替代和新型治疗方法。最后,鉴于HAF的价格低廉、易于获得和安全性,将这种疗法结合起来可能会减少COVID-19导致的死亡和卫生系统的负担,特别是在疫苗获取有限、HAF可广泛获得的国家。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信